GlassScriptPhysician profile
Nirav S Gandhi
NPI 1881791564
$6,530.71
in general payments reported to CMS, 2019-2025
50 companies · $278 in 2025
The $278 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,817 · 2020: $605 · 2021: $1,427 · 2022: $1,296 · 2023: $660 · 2024: $448 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,386.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,559.83 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $480.34 | 2019-2025 | |
| Novo Nordisk INC | $444.38 | 2019-2024 | Wegovy |
| Amgen INC. | $438.24 | 2019-2024 | Krystexxa, Otezla, Repatha |
| Glaxosmithkline, LLC. | $332.23 | 2019-2021 | |
| Pfizer INC. | $319.21 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.30 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $247.08 | 2019-2020 | |
| Lilly USA, LLC | $225.23 | 2021-2024 | Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $181.66 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $180.88 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $162.39 | 2022 | |
| Qol Medical, LLC | $127.47 | 2019 | |
| Esperion Therapeutics, INC. | $106.28 | 2020-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $104.85 | 2021-2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirav Gandhi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.